Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 2, 23 | 0.10 Increased by +132.26% | 0.04 Increased by +150.00% |
| Jul 31, 23 | -0.02 Increased by +91.67% | -0.14 Increased by +85.71% |
| Apr 28, 23 | -0.16 Decreased by -60.00% | -0.25 Increased by +36.00% |
| Mar 1, 23 | -0.23 Decreased by -35.29% | -0.30 Increased by +23.33% |
| Nov 4, 22 | -0.31 Decreased by -72.22% | -0.25 Decreased by -24.00% |
| Jul 29, 22 | -0.24 Decreased by -60.00% | -0.21 Decreased by -14.29% |
| May 6, 22 | -0.10 Increased by +41.18% | -0.21 Increased by +52.38% |
| Feb 25, 22 | -0.17 Decreased by -206.25% | -1.71 Increased by +90.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 113.42 M Increased by +637.72% | 30.75 M Increased by +139.38% | Increased by +27.11% Increased by +105.34% |
| Jun 30, 23 | 83.15 M Increased by +487.16% | -4.25 M Increased by +93.26% | Decreased by -5.11% Increased by +98.85% |
| Mar 31, 23 | 49.87 M Increased by +30.97% | -40.57 M Decreased by -59.47% | Decreased by -81.35% Decreased by -21.77% |
| Dec 31, 22 | 41.17 M Increased by +47.07% | -59.01 M Decreased by -58.74% | Decreased by -143.34% Decreased by -7.94% |
| Sep 30, 22 | 15.38 M Increased by +66.94% | -78.08 M Decreased by -109.11% | Decreased by -507.84% Decreased by -25.26% |
| Jun 30, 22 | 14.16 M Decreased by -16.44% | -62.99 M Decreased by -104.90% | Decreased by -444.77% Decreased by -145.21% |
| Mar 31, 22 | 38.08 M Increased by +142.44% | -25.44 M Increased by +25.29% | Decreased by -66.80% Increased by +69.19% |
| Dec 31, 21 | 27.99 M Decreased by -67.37% | -37.17 M Decreased by -218.43% | Decreased by -132.80% Decreased by -462.99% |